All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Update in T-cell recruiting antibody constructs for the treatment of AML
Bookmark this article
During the 2020 Annual Meeting of the Society of Hematologic Oncology (SOHO), the AML Hub spoke to Marion Subklewe, LMU Munich, Munich, DE, who provided an update in T-cell recruiting antibody constructs for the treatment of AML.
Update in T-cell recruiting antibody constructs for the treatment of AML
Marion Subklewe highlights the different approaches to antibody-based therapeutics in AML, and the challenge of selecting suitable target antigens.
There are a number of T-cell recruiting antibody constructs in phase I clinical trials, which were the focus of this talk. In particular, Marion Subklewe discusses the CD33/CD3 bispecific T-cell engagers, AMG 330 and AMG 673, and the corresponding clinical trials.
Newsletter
Subscribe to get the best content related to AML delivered to your inbox